Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.85 |
| ▸ | MTOR | P42345 | 17/20 | 0.85 |
| ▸ | PIK3C2B | O00750 | 17/20 | 0.85 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.85 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17857423 | 0.92 | PIK3CD (1.00) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB | |
| SCHEMBL17857175 | 0.90 | PIK3CD (0.82) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB | |
| SCHEMBL17857314 | 0.90 | PIK3CD (1.00) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB | |
| SCHEMBL17857183 | 0.86 | PIK3CD (1.00) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB | |
| SCHEMBL17857362 | 0.85 | PIK3CD (0.81) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB | |
| SCHEMBL17857422 | 0.83 | PIK3CD (0.78) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB | |
| SCHEMBL21120082 | 0.83 | PIK3CD (0.86) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB | |
| SCHEMBL19760623 | 0.81 | PIK3CD (1.00) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB | |
| SCHEMBL17857489 | 0.80 | PIK3CD (0.84) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB | |
| SCHEMBL17857375 | 0.80 | PIK3CD (1.00) | PIK3CDMTORPIK3C2BPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016097347-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | WO | disclosed |